JERUSALEM — Teva Pharmaceutical Industries has added a University of California at Los Angeles medical professor to its board of directors, the Israeli drug maker said.
Teva announced the appointment of Arie Belldegrun, who is a director at the UCLA Institute of Urology Oncology and professor and chair of urologic oncology at the David Geffen School of Medicine. The company appointed Belldegrun at its Feb. 5 meeting to fill a vacancy, and Belldegrun's term will extend the drug maker's 2013 annual shareholder meeting.
"We are pleased to welcome Dr. Belldegrun to our board," Teva chairman Phillip Frost said. "Arie's extensive experience in the pharmaceutical industry both as a doctor, a business leader and an academic will enable him to make significant contributions to the board immediately and help guide us as well look for new and innovative ways to bring medicines to patients around the world and continue to increase value for our shareholders."